FDA Clears Next-Generation Contrast Management System for Image-Guided Cardiovascular Procedures
The ACIST Pro Diagnostic System, a variable-rate contrast management platform, reportedly offers real-time contrast tracking for image-guided interventional cardiology procedures and reduces set-up time by one-third in comparison to the ACIST CVI device.
The Food and Drug Administration (FDA) has cleared the ACIST Pro Diagnostic System, which may offer enhanced precision and efficiency in contrast management for image-guided cardiovascular procedures.
Bracco Imaging noted that the ACIST Pro Diagnostic System is a next-generation update of the automated contrast injection platform ACIST CVi. Automated contrast delivery with ACIST CVi has demonstrated average reductions of five minutes in case time and 45 ml in contrast use as well as a 30 percent reduction in contrast-induced acute kidney injuries, according to Bracco Imaging.
The company added that new features with the ACIST Pro Diagnostic System — new peri-pump design, flush bag and faster filling syringe — may reduce set-up time by 33 percent in comparison to the ACIST CVi device.
"By helping clinicians move from uncertainty to confidence at the point of diagnosis, we are supporting more informed decisions with the goal of improving patient outcomes. We are proud to introduce this solution to the U.S. market and look forward to the positive impact it will have,” noted Fulvio Renoldi Bracco, the vice-chairman and CEO of Bracco Imaging.
Related to this article
